Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study (PARCERII)
Cervical Cancer, Endometrial Cancer
About this trial
This is an interventional treatment trial for Cervical Cancer focused on measuring Hypofractionated Radiation, Radiotherapy, Adjuvant, Radiotherapy, Intensity modulated, Late gastrointestinal and genitourinary toxicities
Eligibility Criteria
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Histologically confirmed diagnosis of cervical cancer post hysterectomy with intermediate or high-risk features, requiring adjuvant EBRT ± concurrent chemotherapy OR histologically confirmed diagnosis of endometrial cancer post hysterectomy requiring adjuvant (chemo)radiotherapy to pelvis with/without vaginal brachytherapy. Exclusion Criteria: Patients with macroscopic residual disease (R+ resection) postoperatively Patients requiring extended field radiotherapy (patients with involved para-aortic lymph nodes in cervical or endometrial cancer) Patients treated with chemotherapy for any prior malignancy at any time Patients treated with pelvic radiation previously Patients with human immunodeficiency virus infection Any preexisting medical conditions that may interfere with the assessment of genitourinary or gastrointestinal toxicity (This includes patients with irritable bowel syndrome, subacute intestinal obstruction, anal incontinence, hemorrhoids precluding analysis of gastro-intestinal toxicities, urinary incontinence, recurrent urinary tract infections)
Sites / Locations
Arms of the Study
Arm 1
Experimental
Hypofractionated Image guided External Beam Radiation
Adjuvant hypofractionated external beam radiotherapy for post operative patients with cervical or endometrial cancer.